Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]APP311 is a radiolabeled small molecule used as a positron emission tomography (PET) imaging agent. It is labeled with carbon-11, a short-lived positron-emitting isotope, and is designed for use in research and clinical studies to visualize specific molecular targets or physiological processes in vivo. The compound has the molecular formula C17H15F3N2O and an absolute stereochemistry at one center. As a radiopharmaceutical, its primary mechanism of action involves acting as a ligand that binds to specific biological targets, allowing their distribution and density to be imaged using PET technology. The exact biological target of [11C]APP311 is not specified in the available data; however, it functions as a radioligand for PET imaging applications[1]. Its development aligns with the broader use of carbon-11-labeled tracers for non-invasive imaging of metabolism, synaptic function, or receptor expression in tissues such as brain or heart[2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]APP311.